000143136 001__ 143136
000143136 005__ 20240229105153.0
000143136 0247_ $$2doi$$a10.1111/nan.12397
000143136 0247_ $$2pmid$$apmid:28295484
000143136 0247_ $$2ISSN$$a0305-1846
000143136 0247_ $$2ISSN$$a1365-2990
000143136 0247_ $$2altmetric$$aaltmetric:33686796
000143136 037__ $$aDKFZ-2019-00745
000143136 041__ $$aeng
000143136 082__ $$a610
000143136 1001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b0$$eFirst author$$udkfz
000143136 245__ $$aWHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours.
000143136 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2018
000143136 3367_ $$2DRIVER$$aarticle
000143136 3367_ $$2DataCite$$aOutput Types/Journal article
000143136 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1552901209_3634$$xReview Article
000143136 3367_ $$2BibTeX$$aARTICLE
000143136 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143136 3367_ $$00$$2EndNote$$aJournal Article
000143136 520__ $$aThis short review highlights significant changes and recent findings incorporated to varying extent in the WHO 2016 definition of a variety of tumours, including peripheral nerve sheath tumours, meningiomas, mesenchymal nonmeningothelial tumours, melanocytic tumours, lymphomas and histiocytic tumours, germ cell tumours and non-neuroendocrine pituitary tumours. Most notable classification changes include: adding hybrid nerve sheath tumours to the spectrum of benign nerve sheath tumours; an updated definition of atypical meningioma (WHO grade II), including cases with brain invasion; recognizing dural solitary fibrous tumour (SFT) and haemangiopericytoma (HPC) as a single tumour entity characterized by NAB2 and STAT6 gene fusions for which the term SFT/HPC was chosen; recognizing that pituitary granular cell tumour, spindle cell oncocytoma, and pituicytoma all share nuclear expression of TTF-1, possibly representing a spectrum of a single nosological entity derived from posterior pituitary glial cells. The most significant diagnostic markers which have emerged include: inactivation of NF1, CDKN2A, and PRC2 components, SUZ12 and EED in MPNST, leading to neurofibromin and H3K27me3 expression loss; GNAQ and GNA11 mutations in CNS primary melanocytic tumours; BRAFV600E mutation in histiocytic tumours (Langerhans cell histiocytosis and Erdheim-Chester disease) and papillary craniopharyngioma, which provides both a diagnostic marker in the appropriate pathological setting and a therapeutic target. The WHO 2016 Classification has balanced cutting-edge knowledge on the molecular characteristics of the miscellaneous CNS tumours reviewed here with a practical approach for their daily diagnostic work-up. Much more progress can be expected in the classification of these neoplasms in the near future.
000143136 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000143136 588__ $$aDataset connected to CrossRef, PubMed,
000143136 7001_ $$0P:(DE-HGF)0$$aReuss, D. E.$$b1
000143136 7001_ $$aGiannini, C.$$b2
000143136 773__ $$0PERI:(DE-600)2008293-9$$a10.1111/nan.12397$$gVol. 44, no. 2, p. 163 - 171$$n2$$p163 - 171$$tNeuropathology & applied neurobiology$$v44$$x0305-1846$$y2018
000143136 909CO $$ooai:inrepo02.dkfz.de:143136$$pVDB
000143136 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143136 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143136 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000143136 9141_ $$y2018
000143136 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143136 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143136 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143136 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROPATH APPL NEURO : 2017
000143136 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143136 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143136 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143136 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143136 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143136 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143136 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143136 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143136 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROPATH APPL NEURO : 2017
000143136 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x0
000143136 980__ $$ajournal
000143136 980__ $$aVDB
000143136 980__ $$aI:(DE-He78)G380-20160331
000143136 980__ $$aUNRESTRICTED